Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

SYDNEY, July 10, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncologyfocused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma (NCT03522298), a life-threatening brain cancer, where there is an urgent unmet need for new therapeutics. GBM AGILE is an adaptive phase II/III global trial sponsored by the Global Coalition for Adaptive Research (GC ...